In addition to improving immediate patient outcomes, the project will allow the
researchers to build a better picture of levels of drug resistance in stricken areas.
It will also give them information on population impacts of anti-malarial interventions.
Clinical trials of the device are expected to begin within three years, after which it will
be brought to market.